BioDelivery Sciences' Onsolis, a cancer pain treatment that makes use of the company's buccal delivery platform, picked up a new FDA approval for a reformulation of the treatment, which is expected to return to the U.S. market in 2016. BioDelivery earlier this year pulled out of a commercialization partnership with Sweden's Meda, which decided to focus more on respiration, and BioDelivery is currently looking for a new partner.
Warren, NJ-based MonoSol Rx aims to get compensated after rival BioDelivery Sciences International ($BDSI) received $60 million in revenue from drug-delivery tech that is included in a
Oral thin films are a potentially game-changing drug-delivery technology. So, unfortunately, it is only natural that as companies compete for position in this space lawyers would have to get
Raleigh, NC-based BioDelivery Sciences International has disclosed a July meeting with the FDA and Swedish pharmaceutical company Meda regarding the Onsolis cancer-pain treatment. The talks centered